The reporter learned from Sinopharm Group on the 26th that the world's first oral hexavalent live attenuated rotavirus vaccine developed by Sinopharm Group China Biology Wuhan Institute of Biological Products successfully completed the first dose in Wuhan. This marks an important breakthrough in the development and application of children's vaccines, and has injected new impetus into the construction of a child health protection system.

The reporter learned from Sinopharm Group on the 26th that the world's first oral hexavalent live attenuated rotavirus vaccine developed by Sinopharm Group China Biology Wuhan Institute of Biological Products successfully completed the first dose in Wuhan. This marks an important breakthrough in the development and application of children's vaccines, and has injected new impetus into the construction of a child health protection system.